Article

Sponsored Content

Buy vs. Build: Bioanalytical lab

Author(s):

Pyxant

With so many outsourcing/insourcing options across drug development workflows, pharmaceutical companies are faced with finding the right partner to fit the needs of their unique molecule. There are criteria to consider when outweighing the benefits and risks associated with buying or building a bioanalytical lab.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Content
Site Logo
July 31st 2025

The Roadmap to Asset Performance Management in Life Science

BlueMountain
Site Logo
July 31st 2025

Unlock the Future of Enterprise Asset Management with Agentic AI

BlueMountain
Site Logo
July 31st 2025

From Maintenance to Compliance: A Guide to CMMS/EAM Readiness

BlueMountain
Site Logo
July 31st 2025

Executive Summary: End-To-End Regulatory CDMO Solutions: Development, Manufacturing, and Approval

Lonza
The road to market access is long and complex. Choosing a CDMO with experienced staff can prove vital to success. In this executive summary, Praveenkumar Devakadaksham and Dr. Roché Marcel Walliser explain all the ways they help make the journey from pharmaceutical development to commercial distribution as smooth as possible. Learn more about:
Site Logo
July 31st 2025

Executive Summary: Keys to Supplying Decentralized Trials: The Value of Direct-to-Patient Solutions and the Pharmacy-Led Model

Catalent
Site Logo
July 31st 2025

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent